The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 529-540

  Muñoz, Miguel ^a   González Ortega, Ana ^a   Coveñas, Rafael ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

B ALL SD 1 cell line; L 732,138; L 733,060; Substance P. Apoptosis; T ALL BE 13 cell line

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; APREPITANT; COMPLEMENTARY DNA; MESSENGER RNA; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3,5 BIS(TRIFLUOROMETHYL)BENZYL N ACETYLTRYPTOPHAN; 3,5-BIS(TRIFLUOROMETHYL)BENZYL N-ACETYLTRYPTOPHAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; PIPERIDINE DERIVATIVE; SUBSTANCE P; TRYPTOPHAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHILD; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; WESTERN BLOTTING; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MORPHOLINES; PIPERIDINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NEUROKININ-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; SUBSTANCE P; TRYPTOPHAN;

EID: 84861738830     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9594-0     Document Type: Article

References (42)

1. Ries LA, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (1999) SEER cancer statistics review, 1973-1996. National Cancer Institute, Bethesda
2. Pui CH, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350:1535-1548
3. Muñoz M, Rosso M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17:504-513
4. Ziche M, Morbidelli L, Pacini M, Gepetti P, Alessandri G, Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvas Res 40:264-278
5. Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signalling pathway. Cancer Res 56:4983-4991
6. Muñoz M, Rosso M, Pérez A, Coveñas R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733, 060 and the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39:427-432
7. Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Soult JA, Montero I (2005) Antitumoral action of the neurokinin-1-receptor antagonist L-733, 060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 46:2567-2570
8. Muñoz M, Rosso M, Coveñas R (2006) The NK-1 receptor is involved in the antitumoural action of L-733, 060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discovery 3:323-329
9. Muñoz M, Rosso M, Soult JA, Coveñas R (2006) Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines. In: Yang AV (ed) Brain cancer: therapy and surgical intervention. Nova Science, New York, pp 45-75
10. Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F (2008) NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26:111-118
11. Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M (2008) The NK-1 receptor is involved in the antitumor action of L-733, 060 and in the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 29:245-254
12. Muñoz M, Rosso M, González-Ortega A, Coveñas R (2010) The NK-1 receptor antagonist L-732, 138 induces apoptosis and counteracts substance P-related mitogenesis in human melanoma cell lines. Cancers 2:611-623
13. Rameshwar P, Gascón P (1995) Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: potential autoregulatory role for these cytokines in SP receptor expression and induction. Blood 86:482-490
14. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231-238
15. Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786-792
16. Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 97:1388-1393
17. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 83:731-742
18. Esteban F, González-Moles MA, Castro D, Martín-Jaén MDM, Redondo M, Ruiz-Avila I, Muñoz M (2009) Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54:258-260
19. Muñoz M, Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV (2008) Immunolocalization of the neurokinin-1 receptor: a new target in the treatment of the human primary retinoblastoma. In: Bospene EB (ed) Focus on eye neoplasma research progress. Nova Science, New York, pp 157-178
20. Muñoz M, Rosso M, Robles-Frías MJ, Salinas-Martín MV, Coveñas R (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90:1259-1269
21. Payan DG, McGillis JP, Organist ML (1986) Binding characteristics and affinity labeling of protein constituents of the human IM-9 lymphoblast receptor for substance P. J Biol Chem 261:14321-14329
22. Nowicki M, Miskowiak B, Ostalska-Nowicka D (2003) Detection of substance P and its mRNA in human blast cells in childhood lymphoblastic leukaemia using immunocytochemistry and in situ hybridisation. Folia Histochem Cytobiol 41:33-36
23. Harrison T, Owens AP, Willians BJ, Swain CJ, Baker R, Hutson PH, Sadowski S, Cascieri MA (1995) Piperidine-ether based hNK1 antagonists 2: investigation of the effect of N-substitution. Bioorg Med Chem Lett 5:209-212
24. Muñoz M, Pérez A, Coveñas R, Rosso M, Castro E (2004) Antitumoural action of L-733, 060 on neuroblastoma and glioma cell lines. Arch Ital Biol 142:105-112
25. Muñoz M, Pérez A, Rosso M, Zamarriego C, Rosso R (2004) Antitumoural action of NK1 receptor antagonist L-733, 060 on human melanoma cell lines. Melanoma Res 14:183-188
26. Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonists, L-732, 138. Invest Ophthalmol Vis Sci 48:2775-2781
27. Muñoz M, Rosso M, Coveñas R (2007) NK-1 receptor antagonists as new anti-tumoural agents: action on human neuroblastoma cell lines. In: Fernandes JA (ed) Focus on neuroblastoma research. Nova Science, New York, pp 31-56
28. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-knowles E, Halle JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlsson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645
29. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ (2000) The novel NK-1 receptor antagonist MK-0869 (L-754, 030) and its water soluble phosphoryl prodrug, L-758, 298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39:652-663
30. Muñoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28:187-193
31. Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C (2005) Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 16:1083-1089
32. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Büchler MW (2000) Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88:12-20
33. Shrikhande SV, Friess H, di Mola FF, Tempia-Caliera A, Conejo Garcia JR, Zhu Z, Zimmermann A, Büchler MW (2001) NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain 91:209-217
34. Moneo V, Serelde BG, Leal JFM, Blanco-Aparicio C, Díaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A (2007) Levels of p27kip1 determine Aplidin sensitivity. Mol Cancer Ther 6:1310-1316
35. 11] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Commun 199:1313-1319
36. Esteban F, Muñoz M, González-Moles MA, Rosso M (2006) A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 25:137-145
37. Akazawa T, Kwatra KG, Goldsmith LE, RichardsonMD CEA, Sampson JH, Kwatra MM (2009) A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109:1079-1086
38. Aguayo A, Giles F, Albitar M (2003) Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 44:213-222
39. Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F (2009) Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinasedependent mechanism. J Biol Chem 284:9280-9289
40. Fackler OT, Grosse R (2008) Cell motility through plasma membrane blebbing. J Cell Biol 181:879-884
41. Nowicki M, Miskowiak B (2003) Substance P - a potent risk factor in childhood lymphoblastic leukaemia. Leukemia 17:1096-1099
42. Palma C, Bigioni M, Irrissuto C (2000) Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82:480-487